While both agents seemed very active, ephrinA1-Fc caused a more sustained and extensive decrease in EphA2 levels even at day 3 after treatment, compared to prostate cancer cells treated with 135H12, where EphA2 levels returned after 2 days of treatment (Figure 2b). This evidence concerns the gene EPHA2 and prostate carcinoma.